{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:14:53Z","timestamp":1787890493225,"version":"build-2784847793"},"reference-count":43,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Open Pharma"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,4,7]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Open Science aims to fight misinformation and improve trust in scientific research; it encourages the reliability and accessibility of evidence, reduces inequalities through the democratisation of scientific knowledge and focuses scientific endeavours on issues of societal significance. As a multisponsor collaboration committed to driving positive change, Open Pharma has a multifaceted vision for scientific research publications funded by pharmaceutical companies (\u2018company research publications\u2019) that aligns strongly with Open Science tenets. This new vision statement outlines our forward-looking principles for company research publications, both for short-term attainment (\u2018immediate\u2019) and long-term commitment (\u2018ultimate\u2019). Together, the principles provide a framework for positive collective action by all stakeholders involved in the development and dissemination of peer-reviewed company research publications. Underpinned by our central commitment to transparency for company research publications, we outline goals for: universal access to these publications; provision of peer-reviewed plain language summaries of the publications to aid comprehension among non-specialist readers; leveraging author and institutional metadata to advance transparency, discoverability and research impact; working towards FAIR (Findability, Accessibility, Interoperability, and Reuse) data principles through cross-sector consensus and action, and disclosure of patient involvement in research and its reporting to support transparency and encourage a research ecosystem attuned to patient centricity. We call on all stakeholders to realise the Open Pharma Vision and achieve an open and trusted future for company research publications that will ultimately advance patient care and improve global health.<\/jats:p>","DOI":"10.1136\/bmjopen-2025-104128","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:05:11Z","timestamp":1778249111000},"page":"e104128","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["An Open Pharma Vision for company-sponsored biomedical research publications"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-5370","authenticated-orcid":false,"given":"Joana","family":"Os\u00f3rio","sequence":"first","affiliation":[{"name":"Oxford PharmaGenesis, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8072-5690","authenticated-orcid":false,"given":"Sl\u00e1vka","family":"Bar\u00f3nikov\u00e1","sequence":"additional","affiliation":[{"name":"Alfasigma Belgium BV, Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0941-5379","authenticated-orcid":false,"given":"Sally-Anne","family":"Dews","sequence":"additional","affiliation":[{"name":"Pfizer Ltd, Tadworth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9305-3966","authenticated-orcid":false,"given":"Santosh","family":"Mysore","sequence":"additional","affiliation":[{"name":"GSK, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4180-1560","authenticated-orcid":false,"given":"Kalliopi","family":"Patrikis","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-6027","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Philippon","sequence":"additional","affiliation":[{"name":"UCB, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8331-8759","authenticated-orcid":false,"given":"Christopher P","family":"Rains","sequence":"additional","affiliation":[{"name":"CPR BioPharma Consulting, Newburyport, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-8774","authenticated-orcid":false,"given":"Anja","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5220-2566","authenticated-orcid":false,"given":"Catherine","family":"Skobe","sequence":"additional","affiliation":[{"name":"Pfizer, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3267-3990","authenticated-orcid":false,"given":"Christopher C","family":"Winchester","sequence":"additional","affiliation":[{"name":"Oxford PharmaGenesis, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"2026062608315854000_16.5.e104128.1","doi-asserted-by":"crossref","unstructured":"Gordon J . Open Pharma: Driving Positive Change in the Communication of Pharma-Sponsored Research. AMWA 2023;38. doi:10.55752\/amwa.2023.276","DOI":"10.55752\/amwa.2023.276"},{"key":"2026062608315854000_16.5.e104128.2","unstructured":"UNESCO . UNESCO Recommendation on Open Science. 2021. Available: https:\/\/unesdoc.unesco.org\/ark:\/48223\/pf0000379949\/PDF\/379949eng.pdf.multi [Accessed 19 Dec 2024]."},{"key":"2026062608315854000_16.5.e104128.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2018-111145"},{"key":"2026062608315854000_16.5.e104128.4","unstructured":"Open Pharma. YouTube . Open Pharma Summit 2023: Road towards more open access. 2024. Available: https:\/\/www.youtube.com\/watch?v=zL8Pg6A33Xg [Accessed 12 Feb 2026]."},{"key":"2026062608315854000_16.5.e104128.5","unstructured":"Nobes S . Open Pharma blog article: Open Pharma summit: a new vision for pharma communications. 2024. Available: https:\/\/www.openpharma.blog\/blog\/transparency\/data\/open-pharma-summit-a-new-vision-for-pharma-communications\/ [Accessed 12 Feb 2026]."},{"key":"2026062608315854000_16.5.e104128.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1987"},{"key":"2026062608315854000_16.5.e104128.7","doi-asserted-by":"crossref","unstructured":"Warren M . Big pharma is embracing open-access publishing like never before. Nature New Biol 2019. doi:10.1038\/d41586-019-00610-2","DOI":"10.1038\/d41586-019-00610-2"},{"key":"2026062608315854000_16.5.e104128.8","unstructured":"Open Pharma . Position statement on Open Access. 2019. Available: https:\/\/www.openpharma.blog\/position-statement-on-open-access\/ [Accessed 04 Nov 2024]."},{"key":"2026062608315854000_16.5.e104128.9","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8460.3","article-title":"The academic, economic and societal impacts of Open Access: an evidence-based review","volume":"5","author":"Tennant","year":"2016","journal-title":"F1000Res"},{"key":"2026062608315854000_16.5.e104128.10","unstructured":"Dutch National website . Creative Commons licenses. Available: https:\/\/www.openaccess.nl\/en\/creative-commons-licenses [Accessed 19 Dec 2024]."},{"key":"2026062608315854000_16.5.e104128.11","unstructured":"Crossref . Documentation. Available: https:\/\/www.crossref.org\/documentation\/reference-linking\/ [Accessed 13 Mar 2025]."},{"key":"2026062608315854000_16.5.e104128.12","unstructured":"Unpaywall . An open database of 52,824,104 free scholarly articles. Available: https:\/\/unpaywall.org\/ [Accessed 16 Apr 2025]."},{"key":"2026062608315854000_16.5.e104128.13","unstructured":"Budapest Open Access Initiative . Read the Declaration. Budapest Open Access Initiative. 2021. Available: https:\/\/www.budapestopenaccessinitiative.org\/ [Accessed 19 Dec 2024]."},{"key":"2026062608315854000_16.5.e104128.14","unstructured":"European Commission . EU Support for Open Access. Available: https:\/\/research-and-innovation.ec.europa.eu\/strategy\/strategy-research-and-innovation\/our-digital-future\/open-science\/open-access_en [Accessed 3 Mar 2025]."},{"key":"2026062608315854000_16.5.e104128.15","unstructured":"Wellcome . Open Access Policy. Available: https:\/\/wellcome.org\/grant-funding\/guidance\/open-access-guidance\/open-access-policy [Accessed 3 Mar 2025]."},{"key":"2026062608315854000_16.5.e104128.16","unstructured":"Gates Foundation . 2025 Open Access Policy. Available: https:\/\/openaccess.gatesfoundation.org\/open-access-policy\/ [Accessed 3 Mar 2025]."},{"key":"2026062608315854000_16.5.e104128.17","unstructured":"National Institutes of Health . What is the NIH public access policy? Available: https:\/\/www.nih.gov\/health-information\/nih-clinical-research-trials-you\/what-is-nih-public-access-policy [Accessed 3 Mar 2025]."},{"key":"2026062608315854000_16.5.e104128.18","unstructured":"Takeda . Shire Continues to Uphold High Standards of Ethics and Transparency with Adoption of Open Access Policy for Publication of Shire-Supported Research. 2018. Available: https:\/\/www.takeda.com\/newsroom\/shire-news-releases\/2018\/xajhds\/ [Accessed 16 Apr 2025]."},{"key":"2026062608315854000_16.5.e104128.19","unstructured":"Ipsen . Clinical Data Transparency. 2018. Available: https:\/\/www.ipsen.com\/clinical-data-transparency\/ [Accessed 16 Apr 2025]."},{"key":"2026062608315854000_16.5.e104128.20","unstructured":"Galapagos . Galapagos commits to open access policy. 2020. Available: https:\/\/www.glpg.com\/stories\/galapagos-commits-to-open-access-policy\/ [Accessed 16 Apr 2025]."},{"key":"2026062608315854000_16.5.e104128.21","unstructured":"Pfizer Inc . Pfizer enhances discoverability and impact of research with Figshare. 2022. Available: https:\/\/info.figshare.com\/case_study\/pfizer-enhances-discoverability-and-impact-of-research-with-figshare-2\/ [Accessed 15 Apr 2025]."},{"key":"2026062608315854000_16.5.e104128.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028655","article-title":"Open access policies of leading medical journals: a cross-sectional study","volume":"9","author":"Ellison","year":"2019","journal-title":"BMJ Open"},{"key":"2026062608315854000_16.5.e104128.23","doi-asserted-by":"crossref","unstructured":"Else H . Open access is working \u2014 but researchers in lower-income countries enjoy fewer benefits. Nature New Biol 2024. doi:10.1038\/d41586-024-01748-4","DOI":"10.1038\/d41586-024-01748-4"},{"key":"2026062608315854000_16.5.e104128.24","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1080\/03007995.2021.1971185","article-title":"Open Pharma recommendations for plain language summaries of peer-reviewed medical journal publications","volume":"37","author":"Rosenberg","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"2026062608315854000_16.5.e104128.25","unstructured":"International Committee of Medical Journal Editors . Clinical trials. Available: https:\/\/www.icmje.org\/recommendations\/browse\/publishing-and-editorial-issues\/clinical-trial-registration.html [Accessed 19 Dec 2024]."},{"key":"2026062608315854000_16.5.e104128.26","unstructured":"ORCiD . About ORCID. Available: https:\/\/info.orcid.org\/what-is-orcid\/ [Accessed 26 Mar 2025]."},{"key":"2026062608315854000_16.5.e104128.27","unstructured":"Research Organization Registry . What is ROR? Available: https:\/\/ror.org\/about\/ [Accessed 19 Dec 2024]."},{"key":"2026062608315854000_16.5.e104128.28","doi-asserted-by":"crossref","DOI":"10.1186\/s40900-022-00346-w","article-title":"Hidden in plain sight? Identifying patient-authored publications","volume":"8","author":"Oliver","year":"2022","journal-title":"Res Involv Engagem"},{"key":"2026062608315854000_16.5.e104128.29","unstructured":"Rubenstein M , Sujlana D , Young E . Convey Connects Relationship and Financial Interest Disclosures to ORCID Records, 2024. Available: https:\/\/info.orcid.org\/convey-connects-relationship-and-financial-interest-disclosures-to-orcid-records\/ [Accessed 19 Dec 2024]."},{"key":"2026062608315854000_16.5.e104128.30","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2016.18","article-title":"The FAIR Guiding Principles for scientific data management and stewardship","volume":"3","author":"Wilkinson","year":"2016","journal-title":"Sci Data"},{"key":"2026062608315854000_16.5.e104128.31","unstructured":"European Commission . Open Science. Available: https:\/\/research-and-innovation.ec.europa.eu\/strategy\/strategy-2020-2024\/our-digital-future\/open-science_en [Accessed 19 Dec 2024]."},{"key":"2026062608315854000_16.5.e104128.32","unstructured":"SPARC Europe . Setting the default to open: Open\/FAIR Data. Available: https:\/\/sparceurope.org\/what-we-do\/open-data\/ [Accessed 19 Dec 2024]."},{"key":"2026062608315854000_16.5.e104128.33","unstructured":"Aspen Digital . Council for a FAIR Data Future. Available: https:\/\/fairdatafuture.aspendigital.org\/ [Accessed 6 Nov 2024]."},{"key":"2026062608315854000_16.5.e104128.34","unstructured":"World Bank Group . World Bank Open Data: Free and open access to global development data. Available: https:\/\/data.worldbank.org\/ [Accessed 19 Dec 2024]."},{"key":"2026062608315854000_16.5.e104128.35","unstructured":"European Federation of Pharmaceutical Industries and Associations . Sharing clinical trial information. Available: https:\/\/www.efpia.eu\/about-medicines\/development-of-medicines\/regulations-safety-supply\/clinical-trials\/sharing-clinical-trial-information\/ [Accessed 11 Dec 2024]."},{"key":"2026062608315854000_16.5.e104128.36","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMp1610336","article-title":"Data Sharing - Is the Juice Worth the Squeeze?","volume":"375","author":"Strom","year":"2016","journal-title":"N Engl J Med"},{"key":"2026062608315854000_16.5.e104128.37","unstructured":"Os\u00f3rio J , McIlwaine P , Bhatia R , et al . Unraveling the Story Behind Challenges with Journal Data Sharing Requirements: an Open Pharma Survey. 2024 Annual Meeting of the International Society for Medical Publication Professionals (ISMPP). Available: https:\/\/openpharma.figshare.com\/articles\/poster\/Unraveling_the_story_behind_challenges_with_journal_data_sharing_requirements_an_Open_Pharma_survey\/25592898?file=46319998 [accessed 26 Mar 2025]."},{"key":"2026062608315854000_16.5.e104128.38","unstructured":"Pistoia Alliance . The FAIR Toolkit for Life Science Industry. Available: https:\/\/fairtoolkit.pistoiaalliance.org\/ [Accessed 19 Dec 2024]."},{"key":"2026062608315854000_16.5.e104128.39","unstructured":"US Food and Drug Administration . Focus Area: Empowering Patients and Consumers to Make Better-Informed Decisions. 2022. Available: https:\/\/www.fda.gov\/science-research\/focus-areas-regulatory-science-report\/focus-area-empowering-patients-and-consumers-make-better-informed-decisions [Accessed 19 Dec 2024]."},{"key":"2026062608315854000_16.5.e104128.40","unstructured":"European Medicines Agency . Partners and networks: patients and consumers. Available: https:\/\/www.ema.europa.eu\/en\/partners-networks\/patients-consumers [Accessed 19 Dec 2024]."},{"key":"2026062608315854000_16.5.e104128.41","unstructured":"International Committee of Medical Journal Editors . Defining the Role of Authors and Contributors. Available: https:\/\/www.icmje.org\/recommendations\/browse\/roles-and-responsibilities\/defining-the-role-of-authors-and-contributors.html [Accessed 19 Dec 2024]."},{"key":"2026062608315854000_16.5.e104128.42","unstructured":"Bhatia R , Anthony B . Clinical trials: do the patients get the thanks they deserve. Research in Patient Involvement 2012;8."},{"key":"2026062608315854000_16.5.e104128.43","article-title":"When should medical writers be listed as authors","volume":"30","author":"Gristwood","year":"2014","journal-title":"Curr Med Res Op"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-104128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:44:02Z","timestamp":1782488642000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-104128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,8]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjopen-2025-104128"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-104128","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}